Pharmacology, Toxicology and Pharmaceutical Science
HIV
100%
Pharmacokinetics
56%
Tenofovir
52%
Cabotegravir
23%
Dapivirine
22%
Emtricitabine
20%
Human Immunodeficiency Virus Infection
20%
Tenofovir Disoproxil
20%
Placebo
17%
Pharmacodynamics
15%
Clinical Trial
14%
Adverse Event
11%
Tenofovir Alafenamide
10%
Maraviroc
9%
Drug Concentration
9%
Infection
9%
Implant
8%
Tolerability
8%
Fumaric Acid
7%
Microbicide
7%
Levonorgestrel
6%
Glycerol
5%
Antiretrovirus Agent
5%
Randomized Controlled Trial
5%
Rifapentine
5%
Keyphrases
Pre-exposure Prophylaxis (PrEP)
37%
Tenofovir
27%
Pharmacokinetics
26%
HIV Pre-exposure Prophylaxis
20%
Tenofovir Disoproxil Fumarate
17%
Cabotegravir
15%
Dapivirine
14%
HIV Research Network
14%
Emtricitabine
12%
Human Immunodeficiency Virus Type 1 (HIV-1)
12%
AIDS/HIV
11%
HIV Patients
11%
Vaginal Ring
10%
Antiviral Drugs
9%
HIV Infection
9%
Maraviroc
9%
Transgender
9%
Pharmacodynamics
8%
Long-acting Cabotegravir
7%
Tenofovir Alafenamide
7%
Drug Concentration
7%
Oral Pre-exposure Prophylaxis
7%
Long-acting Injectable
7%
Dapivirine Vaginal Ring
7%
Cisgender
7%
Fumarate
6%
Adverse Events
6%
Placebo
6%
Tolerability
6%
Men Who Have Sex with Men
6%
Tenofovir Diphosphate
6%
Human Immunodeficiency Virus Infection
6%
HIV Prevention
5%
Human Immunodeficiency Virus Prevention
5%
United States
5%
Safety Study
5%
Pharmacokinetic Study
5%
Antiretroviral
5%
Medicine and Dentistry
Human Immunodeficiency Virus
39%
Cabotegravir
13%
Pre-Exposure Prophylaxis
13%
Pharmacokinetics
12%
Tenofovir
9%
Vagina Ring
9%
Human Immunodeficiency Virus Infection
8%
Placebo
8%
Dapivirine
8%
Infection
5%